In today’s briefing:
- Who Are Leading the Charge in the RNAissance of Medicine
- APAC Healthcare Weekly (Nov 17)- GenScript Biotech, Eisai, Otsuka, Daiichi Sankyo, Cellid, and Lunit
Who Are Leading the Charge in the RNAissance of Medicine
- In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
- In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US) and Moderna (MRNA US) are best positioned. Among private companies Senda Biosciences screened well.
- Partnerships and acquisitions between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA’s potential versatility, risks and the necessity for RNA related exposure.
APAC Healthcare Weekly (Nov 17)- GenScript Biotech, Eisai, Otsuka, Daiichi Sankyo, Cellid, and Lunit
- GenScript Biotech established operations site and logistics center in Australia. Eisai has received positive opinion from CHMP recommending approval of lecanemab. Otsuka forms JV to boost IV supply in US.
- Lunit formed strategic alliance in France to expand AI solution deployment. Daiichi Sankyo and AstraZeneca submitted a new BLA for accelerated approval in the U.S. for datopotamab deruxtecan for NSCLC.
- Cellid has completed recruiting and dosing all participants in its Phase 3 clinical trial of COVID-19 vaccine targeting Omicron variant. Alembic Pharmaceutical received FDA approval for hypertension drug.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
